论文部分内容阅读
目的:探讨和分析支原体诱发的咳嗽变异性哮喘的治疗方法和治疗效果。方法:将50例经临床确诊的由支原体诱发的咳嗽变异性哮喘患者纳入本次选择范围,将患者分为两组,分别为治疗组和对照组,全部患者均接受常规治疗,在此治疗基础上25例对照组患者接受糖皮质激素治疗,25例治疗组患者接受阿奇霉素治疗,分别对两种不同治疗方式的临床治疗效果进行比较和分析。结果:治疗组共23例患者治疗有效,治疗总有效率为92%,对照组共18例患者治疗有效,治疗总有效率为72%,两组患者治疗效果差异显著,具有统计学意义(P<0.05)。治疗组患者肺功能改善情况明显优于对照组,两组差异具有统计学意义(P<0.05)。结论:将大环内脂类药物应用于支原体诱发的咳嗽变异性哮喘患者的治疗过程中能够使患者病情获得有效改善。
Objective: To investigate and analyze the treatment of mycoplasma-induced cough variant asthma and its therapeutic effect. Methods: 50 cases of clinically diagnosed Mycoplasma-induced cough variant asthma patients were included in this selection, the patients were divided into two groups, respectively, the treatment group and the control group, all patients received conventional treatment, based on this treatment On the 25 patients in the control group were treated with glucocorticoid, 25 patients in the treatment group were treated with azithromycin, respectively, the clinical treatment of two different treatment methods were compared and analyzed. Results: A total of 23 patients in the treatment group were treated effectively. The total effective rate was 92%. Eighteen patients in the control group were treated effectively and the total effective rate was 72%. There was significant difference between the two groups in the treatment effect (P <0.05). The improvement of pulmonary function in the treatment group was obviously better than that in the control group, the difference was statistically significant (P <0.05). Conclusion: The application of macrolide lipids in patients with cough variant asthma induced by mycoplasma can effectively improve the condition of patients.